WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2023)
Top diagnostic & research stocks in 2023 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Exchange
Industry
Zen Score
Market Cap
Price
1d %
EBITDA
P/E
D/E
FLGT
FULGENT GENETICS INC
NASDAQ
Diagnostics & Research
$1.00B$34.00-6.10%$400.34M3.78x0.10
SYNH
SYNEOS HEALTH INC
NASDAQ
Diagnostics & Research
$3.87B$37.58-0.92%$711.83M13.47x1.44
LNTH
LANTHEUS HOLDINGS INC
NASDAQ
Diagnostics & Research
$4.13B$60.02-1.28%$216.34M38.72x0.72
QDEL
QUIDELORTHO CORP
NASDAQ
Diagnostics & Research
$5.89B$89.25-0.50%$1.29B4.71x0.81
BWAY
BRAINSWAY LTD
NASDAQ
Diagnostics & Research
$34.05M$2.03-3.01%-$9.07M-3.17x0.38
DXCM
DEXCOM INC
NASDAQ
Diagnostics & Research
$41.23B$106.73-1.57%$432.20M180.90x1.69
CODX
CO-DIAGNOSTICS INC
NASDAQ
Diagnostics & Research
$87.50M$2.83-4.07%$17.55M5.78x0.10
TMO
THERMO FISHER SCIENTIFIC INC
NYSE
Diagnostics & Research
$225.97B$576.17-1.97%$11.60B32.12x1.08
SHC
SOTERA HEALTH CO
NASDAQ
Diagnostics & Research
$5.02B$17.80-1.93%$404.85M41.40x3.63
DMTK
DERMTECH INC
NASDAQ
Diagnostics & Research
$157.72M$5.22-6.28%-$110.81M-1.36x0.25
QGEN
QIAGEN NV
NYSE
Diagnostics & Research
$11.23B$49.31-0.46%$864.72M23.04x0.96
PHG
KONINKLIJKE PHILIPS NV
NYSE
Diagnostics & Research
$15.03B$17.27-2.48%$5.37B4.14x1.14
TWST
TWIST BIOSCIENCE CORP
NASDAQ
Diagnostics & Research
$1.34B$23.73-6.24%-$191.55M-5.87x0.22
CSTL
CASTLE BIOSCIENCES INC
NASDAQ
Diagnostics & Research
$703.85M$26.71-5.62%-$54.33M-13.03x0.11
DGX
QUEST DIAGNOSTICS INC
NYSE
Diagnostics & Research
$16.56B$145.391.81%$2.19B13.99x1.12
DRIO
DARIOHEALTH CORP
NASDAQ
Diagnostics & Research
$132.09M$5.6710.53%-$66.94M-1.77x0.42
SENS
SENSEONICS HOLDINGS INC
NYSEMKT
Diagnostics & Research
$535.65M$1.12-6.67%$234.25M2.29x-13.13
MEDP
MEDPACE HOLDINGS INC
NASDAQ
Diagnostics & Research
$7.20B$231.67-1.87%$307.01M34.12x2.80
CDNA
CAREDX INC
NASDAQ
Diagnostics & Research
$870.52M$16.26-1.69%-$62.13M-11.53x0.25
LHDX
LUCIRA HEALTH INC
NASDAQ
Diagnostics & Research
$13.44M$0.33-2.65%-$133.85M-0.09x2.11
GENE
GENETIC TECHNOLOGIES LTD
NASDAQ
Diagnostics & Research
$32.69M$1.77-2.75%-$5.03M-5.24x0.27
ICLR
ICON PLC
NASDAQ
Diagnostics & Research
$19.40B$237.74-2.57%$1.30B40.99x1.08
SERA
SERA PROGNOSTICS INC
NASDAQ
Diagnostics & Research
$43.42M$1.400.00%-$45.84M-1.24x0.09
BNGO
BIONANO GENOMICS INC
NASDAQ
Diagnostics & Research
$525.56M$1.77-5.35%-$112.17M-4.32x0.15
A
AGILENT TECHNOLOGIES INC
NYSE
Diagnostics & Research
$45.07B$152.24-1.49%$1.91B36.33x0.99
BIOC
BIOCEPT INC
NASDAQ
Diagnostics & Research
$8.82M$0.52-2.64%-$14.01M-0.52x0.86
PSNL
PERSONALIS INC
NASDAQ
Diagnostics & Research
$178.37M$3.88-0.51%-$95.13M-1.71x0.31
DHR
DANAHER CORP
NYSE
Diagnostics & Research
$192.00B$263.75-2.26%$10.63B28.67x0.72
LH
LABORATORY CORP OF AMERICA HOLDINGS
NYSE
Diagnostics & Research
$21.66B$244.50-1.94%$3.26B12.95x0.96
CHEK
CHECK-CAP LTD
NASDAQ
Diagnostics & Research
$33.66M$5.7836.00%-$19.43M-1.31x0.10
WAT
WATERS CORP
NYSE
Diagnostics & Research
$20.02B$337.04-1.27%$993.31M29.28x6.97
NRC
NATIONAL RESEARCH CORP
NASDAQ
Diagnostics & Research
$1.14B$46.20-0.30%$52.42M33.24x0.99
MOTS
MOTUS GI HOLDINGS INC
NASDAQ
Diagnostics & Research
$5.35M$1.154.55%-$17.60M-0.12x21.79
HSKA
HESKA CORP
NASDAQ
Diagnostics & Research
$934.14M$86.29-2.48%-$4.29M-54.96x0.40
NEOG
NEOGEN CORP
NASDAQ
Diagnostics & Research
$4.30B$19.89-1.97%$63.32M397.80x0.47
PRPO
PRECIPIO INC
NASDAQ
Diagnostics & Research
$20.56M$0.90-0.99%-$10.56M-1.73x0.29
NEO
NEOGENOMICS INC
NASDAQ
Diagnostics & Research
$1.48B$11.74-6.45%-$95.80M-8.83x0.73
MTD
METTLER TOLEDO INTERNATIONAL INC
NYSE
Diagnostics & Research
$34.69B$1,555.98-2.24%$1.19B42.14x-40.78
MXCT
MAXCYTE INC
NASDAQ
Diagnostics & Research
$555.13M$5.44-5.72%-$21.32M-23.65x0.13
BNR
BURNING ROCK BIOTECH LTD
NASDAQ
Diagnostics & Research
$314.85M$3.03-0.33%N/A-2.26x0.33
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
NYSE
Diagnostics & Research
$12.56B$246.91-1.37%$864.40M28.64x1.79
IDXX
IDEXX LABORATORIES INC
NASDAQ
Diagnostics & Research
$40.21B$485.530.65%$983.30M61.00x4.55
ME
23ANDME HOLDING CO
NASDAQ
Diagnostics & Research
$1.18B$2.60-3.35%-$284.35M-3.61x0.27
IQV
IQVIA HOLDINGS INC
NYSE
Diagnostics & Research
$43.15B$232.31-2.05%$2.87B37.11x3.53
ONVO
ORGANOVO HOLDINGS INC
NASDAQ
Diagnostics & Research
$14.38M$1.65-1.49%-$11.76M-1.20x0.12
STIM
NEURONETICS INC
NASDAQ
Diagnostics & Research
$166.05M$6.10-5.13%-$31.07M-4.49x0.89
RNLX
RENALYTIX PLC
NASDAQ
Diagnostics & Research
$108.97M$2.91-2.68%-$46.60M-2.31x1.06
CNTG
CENTOGENE NV
NASDAQ
Diagnostics & Research
$36.56M$1.353.45%-$26.71M-0.53x3.27
MYGN
MYRIAD GENETICS INC
NASDAQ
Diagnostics & Research
$1.54B$19.01-4.76%-$65.30M-19.60x0.32
XGN
EXAGEN INC
NASDAQ
Diagnostics & Research
$46.02M$2.820.36%-$35.38M-1.21x0.81
RDNT
RADNET INC
NASDAQ
Diagnostics & Research
$1.21B$21.04-2.37%$244.37M175.33x5.72
AWH
ASPIRA WOMEN's HEALTH INC
NASDAQ
Diagnostics & Research
$67.82M$0.55-1.80%-$30.74M-2.02x1.14
NTRA
NATERA INC
NASDAQ
Diagnostics & Research
$4.27B$43.78-2.25%-$508.04M-7.69x1.79
BVS
BIOVENTUS INC
NASDAQ
Diagnostics & Research
$152.37M$1.96-6.67%-$108.32M-0.95x2.97
PKI
PERKINELMER INC
NYSE
Diagnostics & Research
$17.42B$137.90-2.72%$1.40B27.86x0.96
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA INC
NASDAQ
Diagnostics & Research
$2.56B$11.33-2.16%-$266.64M-8.33x1.90
ANIX
ANIXA BIOSCIENCES INC
NASDAQ
Diagnostics & Research
$135.12M$4.37-4.38%-$13.55M-9.71x0.08
OLK
OLINK HOLDING AB (PUBL)
NASDAQ
Diagnostics & Research
$2.37B$19.93-0.10%-$7.65M-94.90x0.16
SRDX
SURMODICS INC
NASDAQ
Diagnostics & Research
$426.43M$30.190.80%-$16.21M-13.01x0.58
CEMI
CHEMBIO DIAGNOSTICS INC
NASDAQ
Diagnostics & Research
$16.19M$0.440.23%-$30.88M-0.36x2.50
AXDX
ACCELERATE DIAGNOSTICS INC
NASDAQ
Diagnostics & Research
$66.40M$0.67-2.76%-$62.21M-0.69x-8.74
EXAS
EXACT SCIENCES CORP
NASDAQ
Diagnostics & Research
$11.93B$67.14-0.46%-$483.48M-16.34x1.03
OPK
OPKO HEALTH INC
NASDAQ
Diagnostics & Research
$1.04B$1.35-2.88%-$241.53M-3.00x0.37
NDRA
ENDRA LIFE SCIENCES INC
NASDAQ
Diagnostics & Research
$12.86M$4.07-1.21%-$12.77M-0.78x0.21
GTH
GENETRON HOLDINGS LTD
NASDAQ
Diagnostics & Research
$109.41M$1.18-0.84%N/A-1.12x0.46
BMRA
BIOMERICA INC
NASDAQ
Diagnostics & Research
$38.15M$2.83-4.39%-$4.96M-6.58x0.37
NOTV
INOTIV INC
NASDAQ
Diagnostics & Research
$203.06M$7.93-2.34%$63.83MN/A1.67
CELC
CELCUITY INC
NASDAQ
Diagnostics & Research
$160.47M$10.386.24%-$33.45M-4.36x0.50
CDIO
CARDIO DIAGNOSTICS HOLDINGS INC
NASDAQ
Diagnostics & Research
$17.87M$1.8859.32%-$1.27M-2.11x0.06
MYNZ
MAINZ BIOMED NV
NASDAQ
Diagnostics & Research
$97.04M$6.70-2.76%-$23.76M-335.00x0.16
ISPC
ISPECIMEN INC
NASDAQ
Diagnostics & Research
$14.28M$1.63-2.98%-$9.93M-1.94x0.25
VRAX
VIRAX BIOLABS GROUP LTD
NASDAQ
Diagnostics & Research
$9.56M$0.820.00%-$2.59M-1.01x0.26
GH
GUARDANT HEALTH INC
NASDAQ
Diagnostics & Research
$3.03B$29.56-7.45%-$542.29M-4.98x9.21
PMD
PSYCHEMEDICS CORP
NASDAQ
Diagnostics & Research
$31.16M$5.520.18%$678.00k-15.33x0.75
OPGN
OPGEN INC
NASDAQ
Diagnostics & Research
$4.91M$1.835.17%-$27.77M-0.10x1.37
AKU
AKUMIN INC
NASDAQ
Diagnostics & Research
$101.32M$1.1313.00%$69.40M-0.67x-214.46
LAB
STANDARD BIOTOOLS INC
NASDAQ
Diagnostics & Research
$160.18M$2.02-2.88%-$174.48M-0.88x-2.65
HTGM
HTG MOLECULAR DIAGNOSTICS INC
NASDAQ
Diagnostics & Research
$4.48M$4.86-3.57%-$20.08M-0.17x10.26
SQL
SEQLL INC
NASDAQ
Diagnostics & Research
$6.42M$0.54-1.46%-$3.98M-1.59x0.70
VNRX
VOLITIONRX LTD
NYSEMKT
Diagnostics & Research
$124.25M$2.16-3.14%-$29.74M-3.79x6.22
SLNO
SOLENO THERAPEUTICS INC
NASDAQ
Diagnostics & Research
$18.93M$2.32-10.42%-$19.16M-0.70x1.10
ILMN
ILLUMINA INC
NASDAQ
Diagnostics & Research
$32.83B$208.70-2.59%-$3.68B-7.90x0.67
ENZ
ENZO BIOCHEM INC
NYSE
Diagnostics & Research
$66.26M$1.36-4.90%-$23.86M-2.47x0.89
BIAF
BIOAFFINITY TECHNOLOGIES INC
NASDAQ
Diagnostics & Research
$20.09M$2.400.84%N/AN/A0.12
PRE
PRENETICS GLOBAL LTD
NASDAQ
Diagnostics & Research
$174.24M$1.576.80%N/A-0.11x0.30
TTOO
T2 BIOSYSTEMS INC
NASDAQ
Diagnostics & Research
$10.83M$1.485.71%-$55.28M-0.09x-2.39
NVTA
INVITAE CORP
NYSE
Diagnostics & Research
$607.24M$2.50-4.58%-$3.07B-0.18x11.75
BDSX
BIODESIX INC
NASDAQ
Diagnostics & Research
$85.03M$2.024.66%-$46.32M-1.17x-22.77
TRIB
TRINITY BIOTECH PLC
NASDAQ
Diagnostics & Research
$22.78M$1.091.87%N/AN/A13.76
LMDX
LUMIRADX LTD
NASDAQ
Diagnostics & Research
$365.30M$1.200.00%-$101.55M-1.14x6.89
OABI
OMNIAB INC
NASDAQ
Diagnostics & Research
$446.48M$4.02-3.60%N/AN/A0.35
MDXH
MDXHEALTH SA
NASDAQ
Diagnostics & Research
$65.15M$4.002.83%N/AN/A4.71

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Feb 2023?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fulgent Genetics (NASDAQ:FLGT)


Fulgent Genetics (NASDAQ:FLGT) is the top diagnostic & research stock with a Zen Score of 57, which is 27 points higher than the diagnostic & research industry average of 30. It passed 18 out of 33 due diligence checks and has strong fundamentals. Fulgent Genetics has seen its stock lose -48.66% over the past year, underperforming other diagnostic & research stocks by -36 percentage points.

Fulgent Genetics has an average 1 year price target of $45.00, an upside of 32.35% from Fulgent Genetics's current stock price of $34.00.

Fulgent Genetics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Fulgent Genetics, 0% have issued a Strong Buy rating, 66.67% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the second best diagnostic & research stock with a Zen Score of 56, which is 26 points higher than the diagnostic & research industry average of 30. It passed 18 out of 33 due diligence checks and has strong fundamentals. Syneos Health has seen its stock lose -57.89% over the past year, underperforming other diagnostic & research stocks by -46 percentage points.

Syneos Health has an average 1 year price target of $47.57, an upside of 26.59% from Syneos Health's current stock price of $37.58.

Syneos Health stock has a consensus Hold recommendation according to Wall Street analysts. Of the 9 analysts covering Syneos Health, 11.11% have issued a Strong Buy rating, 11.11% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 11.11% have issued a Strong Sell.

3. Lantheus Holdings (NASDAQ:LNTH)


Lantheus Holdings (NASDAQ:LNTH) is the third best diagnostic & research stock with a Zen Score of 55, which is 25 points higher than the diagnostic & research industry average of 30. It passed 18 out of 33 due diligence checks and has strong fundamentals. Lantheus Holdings has seen its stock return 125.55% over the past year, overperforming other diagnostic & research stocks by 138 percentage points.

Lantheus Holdings has an average 1 year price target of $107.25, an upside of 78.69% from Lantheus Holdings's current stock price of $60.02.

Lantheus Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Lantheus Holdings, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Koninklijke Philips Nv (NYSE:PHG)


Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of 5.58%, which is 4 percentage points higher than the diagnostic & research industry average of 1.7%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of 24.8% indicates that its high dividend yield is sustainable for the long-term.

2. Psychemedics (NASDAQ:PMD)


Psychemedics (NASDAQ:PMD) has an annual dividend yield of 3.8%, which is 2 percentage points higher than the diagnostic & research industry average of 1.7%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -52.8% indicates that its dividend yield might not be sustainable for the long-term.

3. National Research (NASDAQ:NRC)


National Research (NASDAQ:NRC) has an annual dividend yield of 1.82%, which is the same as the diagnostic & research industry average of 1.7%. National Research's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. National Research's dividend has shown consistent growth over the last 10 years.

National Research's dividend payout ratio of 60.4% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.71% in the last day, and up 2.27% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Quidelortho (NASDAQ:QDEL)


Quidelortho (NASDAQ:QDEL) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Quidelortho has a valuation score of 86, which is 55 points higher than the diagnostic & research industry average of 31. It passed 6 out of 7 valuation due diligence checks.

Quidelortho's stock has dropped -7.42% in the past year. It has overperformed other stocks in the diagnostic & research industry by 5 percentage points.

2. Fulgent Genetics (NASDAQ:FLGT)


Fulgent Genetics (NASDAQ:FLGT) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fulgent Genetics has a valuation score of 86, which is 55 points higher than the diagnostic & research industry average of 31. It passed 6 out of 7 valuation due diligence checks.

Fulgent Genetics's stock has dropped -48.66% in the past year. It has underperformed other stocks in the diagnostic & research industry by -36 percentage points.

3. Syneos Health (NASDAQ:SYNH)


Syneos Health (NASDAQ:SYNH) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 55 points higher than the diagnostic & research industry average of 31. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -57.89% in the past year. It has underperformed other stocks in the diagnostic & research industry by -46 percentage points.

Are diagnostic & research stocks a good buy now?

46.99% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 13.59% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 37.26x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.